BFM
HEPA

Boothbay Fund Management’s Hepion Pharmaceuticals HEPA Stock Holding History

Boothbay Fund Management’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-45
Closed -$26K – 2381
2022
Q2 		$26K Sell
45
-11
-20% -$9.16K ﹤0.01% 2172
2022
Q1 		$72K Hold
56
– – ﹤0.01% 2144
2021
Q4 		$63K Hold
56
– – ﹤0.01% 1759
2021
Q3 		$85K Sell
56
-99
-64% -$159K ﹤0.01% 1817
2021
Q2 		$307K Buy
+155
New +$284K 0.01% 1265

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Boothbay Fund Management's HEPA Position: Q3 2022 in Review

Boothbay Fund Management sold out of Hepion Pharmaceuticals (HEPA) in Q3 2022, closing a stake of 45 shares — an estimated $26K sold.

Boothbay Fund Management first reported a position in HEPA in Q2 2021 and held it in 5 quarters. The position peaked at $307K in Q2 2021. 25 funds tracked by Wall St. Rank hold HEPA as of Q3 2022.

  • Boothbay Fund Management reported no remaining Hepion Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 45 Hepion Pharmaceuticals shares in Q3 2022, an estimated $26K.
  • Boothbay Fund Management first reported a position in Hepion Pharmaceuticals in Q2 2021 and held it in 5 quarters.
  • Boothbay Fund Management's Hepion Pharmaceuticals position peaked at $307K in Q2 2021.
  • 25 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q3 2022.

Based on Boothbay Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.